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ABSTRACT
Anticancer drugs like gemcitabine (GEM) are used to treat cancers such as, pancreatic
ductal adenocarcinoma (PDAC). However, the use of free gemcitabine yields challenges including
cytotoxicity to healthy cells and poor circulation time. By encapsulating GEM in nanoparticles
these challenges can be overcome. In this study poly(acrylic acid) (PAA)-GEM nanoparticles are
fabricated by coupling GEM onto PAA. The particle formation is driven by the hydrophobic
interaction of GEM, which collects in the core of the nanoparticle, forming a PAA shell. The
nanoparticles were optimized by studying the PAA/GEM ratio and pH during fabrication.
Characteristics of the nanoparticles including size, morphology and surface charge were
investigated using dynamic light scattering (DLS), transmission electron microscopy (TEM) and
zeta potential measurements. Conditions such as ionic stability and pH stability were optimized to
achieve high drug loading efficiency. Cell uptake and cytotoxicity studies were used to determine
the efficiency of the nanoparticles as drug delivery vehicle.
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CHAPTER ONE: INTRODUCTION
Polymeric Nanoparticles
With the eruption of nanotechnology and their many applications, the focus on
nanomaterials has increased in the last few decades.1, 2 Platforms such as nanoparticles which range
from a few nanometers to 100 nm, have shown great promise because of their surface area to
volume ratio compared to bulk materials.

1-4

As a result of their physical and chemical

characteristics, nanoparticles are effective in applications such as drug delivery3, antimicrobial
interactions5, catalysis6, energy storage7. A wide variety of nanoparticles are used, including
metals8, quantum dots9, liposomes10 and polymeric11 nanoparticles and they all present some
advantages and shortcomings.
Important factors to consider when fabricating nanoparticles are the size and surface
chemistry of the nanoparticles. Using polymers for nanoparticle fabrication allows for tunable
characteristics that rely on the fabrication method of the nanoparticle and the polymers used.12, 13
Natural and synthetic polymers have been used in the formation of polymeric nanoparticles.
Natural polymers have been noted to form more polydispersed particles from each batch. In
contrast, synthetic polymers have been seen to have more controlled size.12 One of the major
advantages of using polymers as the platform for nanoparticle is the biocompatibility and
biodegradability of some natural and synthetic polymers..12, 14
Hydrogel Nanoparticles
Hydrogels are a three-dimensional (3D) network of crosslinked hydrophilic polymers that
can uptake and retain large amounts of fluids without dissolving.15, 16 Their ability to retain fluids
is a result of different functional groups on the polymers such as -OH, -CONH-, -CONH2- and 1

SO3H. These different functional groups within the polymer network also allow the hydrogel to
swell and de-swell by uptaking and releasing fluid based on the environment of the hydrogel. 3, 16
The degree of crosslinking within the hydrogel allows for the resistance in degradation.16 Physical
hydrogels and chemical hydrogels are categories of hydrogels that are based on the method at
which crosslinking happens. Physical crosslinking occurs via intermolecular forces such as
hydrogen bonding, van der Waals interaction and ion dipole.3 Chemical crosslinked hydrogels are
formed by covalent bonds between different functional groups within a polymer. 17
Hydrogel nanoparticles share the unique properties of both nanoparticles and hydrogels.
Hydrogels have similar properties to living tissue as they share a similar consistency, elasticity,
fluid content and porosity.18, 19 As a result, they are ideal candidates for biomedical applications
such as tissue engineering20, drug delivery21, wound healing22, injectable fillers23, and biosensors.24

Drug Delivery Platforms
As previously mentioned, polymeric nanoparticles serve as an optimal candidate for drug
delivery platforms because of their biocompatibility, biodegradability and their tunable
characteristics.12,

13

Additionally, the nanoparticle allows for improved drug efficacy and

protection of the drug from chemical degradation.3 In the case of hydrogel nanoparticles, the
polymers can be highly functionalized based on the surface of the nanoparticle and they exhibit an
excellent drug released mechanism as a result of their swelling and deswelling properties.25
Nanoparticles can also serve as targeting vehicle for drug delivery as they can be decorated with
targeting enzymes to select for specific cell types. 26, 27 Nanoparticles for drug delivery can exist
either as nanocapsules or nanospheres depending on the fabrication of the nanoparticle.
Nanocapsules are hollow nanoparticles in which the drug can be confined within the center of the
2

nanoparticle. Nanospheres are solid uniformly crosslinked particles where the drug is evenly
distributed within the particle.3, 14

Fabrication of Polymeric Nanoparticles
The method by which nanoparticles are fabricated directly affects their size, morphology
and monodispersity, making this area of research very important for downstream applications of
the nanoparticles.1 There are numerous approaches for the fabrication of polymeric nanoparticles
including, emulsion28, dendrimers29, and precipitation.30
In an emulsion, a micelle can be formed to act as templates for the fabrication of polymer
nanoparticles. This type of nanoparticle is fabricated using a small molecule that contains a
hydrophobic and hydrophilic end called an amphiphilic molecule or a surfactant.31 In the
traditional formation of a micelle there are two phases, a water phase and an oil phase, with the
water phase being larger. The amphiphilic molecule will interact with both phases upon agitation
and nanoparticles will form. The nanoparticle will contain an exterior hydrophilic phase and an
internal hydrophobic phase and the formation of the particle is due to the hydrophobic and
hydrophilic interactions of the surfactant and the solvent phase.32-34 In a reverse emulsion the
micelle will have an exterior hydrophobic phase and an internal hydrophilic phase.28 However, the
emulsion method for nanoparticle fabrication can result in non-biocompatible by-products and
multiple purification steps may be required.12
Dendrimers are a type of polymer nanoparticles formed from hyperbranched
polymerization.29, 35 A dendrimer is composed of an atom or a collection of atoms called the core,
and the branches are referred to as the dendrons.35 Dendrimers can be formed by two approaches:
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divergent and convergent.36 The divergent formation of dendrimers begins with the core, which
then grows outwards by reacting with a monomer consisting of three groups, a reactive group and
two dormant groups. The polymerization continues in a step by step manner with more monomer.35
In contrast, the convergent approach begins with the most exterior branches and grows inwards,
this results in the predetermined size.36 However, the fabrication is time consuming and requires
multistep synthesis.35
Nanoprecipitation or solvent displacement is another method to fabricate polymers
nanoparticles. 12, 37 In this method the nanoparticles are formed from the addition of two miscible
solvents (solvent and non-solvent) and magnetic stirring, resulting in immediate formation of
nanoparticles after phase separation.37-39 Typically the polymer and the drug will be in the solvent
phase.39 The formation is due to interfacial deposition after the polymer is displaced from the
solvent phase into the non-solvent phase.12, 37 This method of fabrication is typically easier than
the formation of polymer nanoparticles through emulsion because of its simplicity and lack of
toxic solvents.37
Block polymers are also used in the fabrication of polymeric nanoparticles where the block
polymer consists of two different polymers with different properties. One example of such
nanoparticle is composed of two polymers, one bearing a hydrophobic region and the other a
hydrophilic region. Based on hydrophobic interactions of the polymer and the solvent the block
polymer is formed.40

4

Focus of Research
Currently, pancreatic cancer is the fourth cause of cancer related deaths and is predicted to
become the second position by 2030. This is a result of the difficultly of treatment and early
diagnosis of pancreatic cancer. The 5-year survival rate for pancreatic cancer is only 5%, with 80%
of diagnosed patients anticipated to die within 12 months. The lack of distinctive side effects of
pancreatic cancer results in diagnosis at later stages of the disease, this leads to difficulty in
treatment. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic
cancer consuming > 90% of pancreatic cancer types. PDAC is also the most demanding in regards
to treatment.41 The current treatment methods for PC are futile and better treatment methods are
needed in order to better treat the cancer.
The first line of defense to treat pancreatic cancer is gemcitabine (2’,2’-difluro-2’deoxycytidine) (GEM), an anticancer chemotherapy. GEM is analog to the DNA base
deoxycytidine and inhibits DNA synthesis, resulting in apoptosis of cells (Figure 1).42 However,
gemcitabine has a short plasma half-life and is quickly metabolized by cytidine deaminase into a
non-active form.43 As a result, high concentration of GEM is needed for treatment. An alternative
approach with the protection of GEM can also be investigated.
Nanotechnologies, such as the use of nanoparticles, serve as delivery systems that can be
used to protect the drug of interest and also allow multiple modalities to the system such as
fluorescence and targeting.26,

27

Several studies have already fabricated gemcitabine loaded

nanoparticles with great success.44-46 However, none have driven the formation of the particle from
the hydrophobic regions of gemcitabine.

5

Here, we use poly(acrylic acid) (PAA) a biodegradable and biocompatible polymer for the
formation of nanoparticles.47, 48 The fabrication of the PAA-GEM nanoparticles are achieved
through hydrophobic interactions from the fluorine atoms in GEM. The characteristics including
size, surface charge and stability were investigated. The in vitro release of drug, cell toxicity and
cell uptake of the nanoparticle were also investigated.

6

a

b
Figure 1 Structure of deoxycytidine (a) and gemcitabine (b)
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CHAPTER TWO: MATERIALS AND METHODS
Materials
Poly(acrylic acid) partial sodium salt solution (~240,000 Da, 25%), anhydrous sodium
acetate and rhodamine G6 (95%) was purchased from Sigma Aldrich. Gemcitabine (98%) and
acetic acid was purchased from Acros Organic, Sodium hydroxide was purchased from Fisher
Chemical. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimine (EDC) was purchased from
Oakwood Chemical. PBS was purchased from Corning Cellgro. Fetal Bovine Serum (FBS),
Penicillin Streptomycin and Dulbecco’s Modified Eagle Medium (DMEM) was purchased from
Life Technologies-ThermoFisher Scientific. PANC-1 cells were obtained from American Type
Culture Collection (ATCC).

Nanoparticle Fabrication
The fabrication of PAA-GEM nanoparticles is as followed, GEM was dissolved in a
solution of 10 mg/mL PAA for molar ratios of 1:2, 1:4, 1:8 and 1:16. Each solution was then
adjusted to pH 4 with 1 M NaOH. In each sample a specific amount of 1-ethyl-3-(3dimethylaminopropyl) carbodiimide hydrochloride (EDC) was added, the solution was stirred
overnight via magnetic stirring at ambient conditions. The above solutions were then purified via
centrifugation at 110,000 rpm for 60 minutes at 4 °C via ultra-centrifugate (Sorvall MTX 150
Micro Ultracentrifuge, Thermo Scientific). The supernatant was collected for UV-analysis. The
pellet was resuspended with water, loaded into dialysis tubing (MWCO 12-14 kDa, SpectraPor)
and underwent 3 phases dialysis until the full removal of free GEM, EDC and EDC by-product.
The dialysis product was then frozen and lyophilized.

8

Encapsulation Efficiency and Loading Capacity:
The supernatant collected was then measured through UV-vis spectroscopy (Cary 300 Bio
UV-Visible Spectrophotometer) for analysis of the gemcitabine at the wavelength of 268 nm. The
collected sample was compared against calibrated standards. The following formulas were used to
calculate the encapsulation efficiency (EE) and loading capacity (LC):
𝐸𝐸 =

(Total amount of drug added−Free amount of drug)

𝐿𝐶 =

Total amount of drug

(Total amount of drug−Free amount of drug)
Total weight of lyophilized nanoparticles

∗ 100

∗ 100

(1)

(2)

Nanoparticle Decoration: Rhodamine G6
The lyophilized sample of nanoparticles were resuspended with deionized water (3 mg/mL)
and were bath sonicated for 5 minutes. Under magnetic stirring, 1 mg/mL Rhodamine G6 (RG6)
was introduced to the nanoparticles for a 10,000:1 molar ratio between PAA:RG6. EDC was added
to the solution at a 1:1 molar ratio between EDC:RG6. The solution was then purified following
the same protocol as for pristine PAA-GEM nanoparticles.

Nanoparticle Characterization
At various steps of nanoparticle fabrication, the size and surface charge were characterized
by dynamic light scatter and zeta potential (Malvern Zetasizer, Nano ZS90). The nanoparticles
were examined after initial fabrication and after resuspension in various solvents. The morphology
of the nanoparticles were examined via transmission electron microscopy (TEM) (JEOL TEM1011). Chemical characteristics of the PAA-GEM nanoparticle were determined through Fourier
9

transform infrared spectroscopy (FT-IR) (Perkin Elmer Spectrum 100) and compared against PAA
and GEM.

Nanoparticle Stability
The stability of the nanoparticles was determined by analyzing the size and surface charge
of the nanoparticles for 7 days in different pH environments. Lyophilized samples of PAA-GEM
nanoparticles were resuspended in sodium acetate buffer (pH 3, 4, 5, 6) and phosphate buffer saline
(PBS) at pH 7.4 at a concentration of 3 mg/mL.

In Vitro Drug Release
The release profile of PAA-GEM nanoparticles was investigated, 100 mg of lyophilized
nanoparticle sample was resuspended in 20 mL of PBS and placed in dialysis bags (MWCO 1214 kDa, SpectraPor). The same amount of free GEM was dissolved 20 mL PBS and placed in
dialysis bags. The samples underwent dialysis against 80 mL of PBS in closed containers at
ambient conditions with slight agitation via mechanical stirring. At various time intervals 3 mL of
releasing phase was collected and replaced with 3 mL of fresh PBS. The collected aliquots were
analyzed through UV-spectroscopy at 268 nm and compared against calibrated solutions.

Cytotoxicity Study
Approximately 5000 PANC-1 cells were seeded in each well of 96-well plates and cultured
in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin. Cells were cultured at 37 °C in a humidified 5% carbon
dioxide atmosphere. After overnight cell culture, cells were treated with PAA-GEM nanoparticles
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and equivalent controls at various concentrations for 24, 48, 72 and 96 hours time points. At each
time point cells were thoroughly washed with PBS. Cell viability assay was conducted using
“Celltiter 96 Aqueous One Solution Cell Proliferation Assay” as per the manufacturer’s protocol.
Briefly, 20 µL of the reagent was be added to each well of 96-well plates containing 100 µL of
complete culture medium, and the plate was incubated at 37 °C for 1-4 hours. Absorbance at 490
nm was be measured and plotted against respective time points to obtain a viability curve

Nanoparticle Cellular Uptake
PAA-GEM-RG6 nanoparticles were analyzed for the uptake within PANC-1 cells. PANC1 cells were treated with PAA-GEM-RG6 nanoparticles at various times: 30 minutes, 1 hour, 2
hours, 3 hours, 4 hours, 5 hours, and 6 hours. At the end of the incubation time the cells were
washed with PBS and replaced with clean media. The cells were observed by optical microscopy
for the analysis of nanoparticle uptake.
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CHAPTER THREE: RESULTS
Nanoparticle Fabrication:
The PAA:GEM ratios were investigated for the fabrication of nanoparticles. Table 1
demonstrates, the effect of different PAA:GEM molar ratios 2:1, 4:1, 8:1 and 16:1 on the
nanoparticles being formed. The 8:1 and 16:1 PAA:GEM solutions resulted in clear solutions,
indicating no nanoparticles were formed. In contrast, the 2:1 solution created a cloudy
agglomeration of particles with a size range of 3574 ± 493.1 nm, a PDI (polydispersity index) of
0.264 ± 0.133 and a zeta potential of -23.0 ± 4.42 mV. The 4:1 ratio resulted in an opalescent
solution with monodispersed particles at 69.62 ± 0.419 nm, a PDI of 0.211 ± 0.014 and a zeta
potential of -16.8 ± 1.36 mV.
The effect of EDC:GEM was investigated for the 4:1 and the 8:1 PAA:GEM ratios . As the
concentration of EDC is increased for the 4:1 PAA:GEM samples, the solution became more
cloudy and the size of the nanoparticles increased, resulting in micron sized particles for both the
4:1:4 and 4:1:8 (PAA:GEM:EDC), as shown in table 2. In addition, the PDI increased with the
increased concentration of EDC, resulting in a more polydispersed mixture of nanoparticles. As
previously recorded, the 8:1:2 (PAA:GEM) solution failed to form nanoparticles with a 2:1
EDC:GEM ratio. However, when increased the 4:1 and 8:1 EDC:GEM ratios were able to form
nanoparticles. The 8:1:4 (PAA:GEM:EDC) solution formed 43.38 ± 7.635 nm particles, with a
PDI of 0.401 ± 0.125 and a zeta potential of -16.5 ± 0.529 mV. Interestingly, the 8:1:8
(PAA:GEM:EDC) solution formed smaller nanoparticles at 28.74 ± 0.127 nm, with a PDI of 0.229
± 0.006 and a zeta potential of -15.8 ± 0.802 mV.
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Nanoparticle Charaterization: Size, Morphology and Surface Charge
The sizes and surface charges of the nanoparticles were determined through dynamic light
scattering and zeta potential in the previous section. The particles were measured in many states
including after fabrication and after resuspension in PBS. The particles demonstrated a size of
28.74 ± 0.127 nm after fabrication at pH 4 and when resuspension in PBS the particles
demonstrated a size of 57.84 ± 1.909 nm.
TEM was used to determine the size and morphology of the PAA:GEM nanoparticles. The
nanoparticles demonstrated a spherical morphology with a size of 12.32 ± 1.96 nm, as shown in
Figure 2a. Figure 2b shows a histogram of the size of the nanoparticles, revealing the
monodispersed size of nanoparticles. Table 3 shows the size of PAA-GEM nanoparticles compared
to PAA-GEM-RG6 nanoparticles. Rhodamine G6 attached particle demonstrates a slight increase
in size as well as a more negative zeta potential than the nanoparticles without RG6.

Gemcitabine to Poly(acrylic acid) Conjugation
In order to confirm the conjugation of GEM to PAA, FT-IR was used to determine if new
bond formations had occurred. As gemcitabine was attached to PAA via EDC coupling the
formation of an amide bond was the target. Figure 3, demonstrates the formation of an amide bond
in the PAA-GEM samples with the C=O stretching at 1680-1700 cm-1 as the amide I band. The
amide II band at 1550-1510 cm-1 is also visible on the PAA-GEM measurement. The C-F bond
stretching at 1400-1000 cm-1 from gemcitabine is also shown on the PAA-GEM nanoparticle. The
formation of the amide bond was found in spectrum as well as the C-F band, confirming the
conjugation between PAA and GEM.
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Encapsulation Efficiency and loading capacity:
The encapsulation efficiency (EE) of the particle was determined through indirect analysis
of gemcitabine via investigation of the supernatant of the centrifuged sample. Using the previously
mentioned equations (1) and (2), the EE and LC were determined to be 29.29 ± 1.66 and 9.44%,
respectively.

Nanoparticle Stability
The stability of the PAA-GEM nanoparticles were studied over several days at different
pH environments, from pH 4 to 7.4. Table 3 demonstrates day one of investigation, here as the pH
of the nanoparticles increased the size of the nanoparticles increased as well in the pH 4-6 solutions
in sodium acetate buffer. The surface charge of particles in the pH 4-6 solutions became
increasingly negative as the pH increased. Interestingly, the size of the pH 6 solution was larger
than the pH 7.4 as well as the surface charge of the pH 6 solution was more negative then the pH
7.4 solution. Figures 4 a and 4 b, demonstrate a prolonged study of seven days to observe the
surface charge and size, respectively. Over time, the size of the nanoparticles increased for all pH
solutions. As for the surface charge of the nanoparticles they remained within the same range for
the entirety of the analysis. However, the pH 4 solution was resistant to change throughout and
retained a similar surface charge and size during the prolonged study.

In Vitro Drug Release
The release profile of free GEM and PAA-GEM nanoparticles was studied for 96 hours (5,
10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 12, 24, 48, 72 and 96 hours). Figure 5 demonstrates the
releasing profile of free GEM and PAA-GEM nanoparticles. Free GEM was released at a
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continuous rate with 12.92% released in the first 5 minutes and 95.84% after 6 hours. PAA-GEM
nanoparticles released 1.00% of GEM after 2 hours and at 96 hours, only 6.79% of the total GEM
was released.

Cytotoxicity Study
Cell viability studies were performed to determine the efficiency of the PAA-GEM
nanoparticles against free GEM. As shown in figure 6, free GEM, PAA and PAA-GEM
nanoparticles were compared at different concentrations and time for their cytotoxicity. For the
concentrations of 0.01 µM and 0.1 µM no noticeable differences were observed between the
controls and the nanoparticles for the entire 96 hours. At 24 hours of incubation no significant
differences were seen between the PAA-GEM nanoparticles and free GEM for all the
concentrations studied. After 48 hours cell viability decreased for 5 µM and 10 µM concentrations
for the cell colonies treated with free GEM to 73.7 ± 2.8% and 61.7 ± 4.9%, respectively. At 72
hours free GEM continued to decrease the cell viability for 5 µM and 10 µM to 54.7 ± 2.6 % and
49.5 ± 2.5%, respectively. In addition, the cell viability for the PAA-GEM nanoparticles also
begins to decrease at 72 hours for the 10 µM concentration to 67.2 ± 4.7%. However, there were
still more cells viable in the PAA-GEM cell colonies compared to the free GEM colonies. At 96
hours the cell viability for PAA-GEM nanoparticles was similar to the cell viability of free GEM
for both the 5 µM and 10 µM concentrations. The cells treated with free GEM had cell viability at
56.0 ± 4.6% and 42.1 ± 1.6% for the 5 µM and 10 µM, respectively. The cell viability at 96 hours
for the PAA-GEM nanoparticles was 61.5 ± 3.1 and 44.3 ± 3.7% at 96 hours, respectively.
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Cell Uptake Kinetics
In order to determine the uptake of the nanoparticles within the cell a kinetic study was
designed to observe the amount of fluorescence within cells at various time intervals. Rhodamine
G6 nanoparticles were incubated with PANC-1 cells and the fluorescence at different times was
determined. As shown in figure 7, the kinetic study reveals that the fluorescens intensity increases
from 30 minutes to 2 hours and reaches equilibrium at 2-5 hours.
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a

b
Figure 2- Nanoparticle size. Transmission electron microscopy (TEM) of PAA-GEM NP (a); size distribution
histogram of the nanoparticles from TEM image (b)
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Figure 6 Cell viability study: PANC-1 cells treated with various concentrations of GEM, PAA and PAA-GEM NP at
various time intervals 24 hours (a); 48 hours (b); 72 hours (c); and 96 hours (d).
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Figure 7 Cell uptake kinetics: Fluorescence images and fluorescence/bright-field overlay images of PANC-1 cells
incubated with PAA-GEM-RG6 nanoparticles at 30 min (a, e); 2h(b, f); 4h (c, g); and 6h (d, h).

22

Fluorescence intensity per cell

18000
16000
14000
12000
10000
8000
6000
4000
2000
0
0.5

1

2

3

4

5

6

Time (hours)
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Table 1 Effects of PAA:GEM ratio to nanoparticles size, PDI and zeta potential. 8:1 and 16:1 solutions failed to
make particles
PAA:GEM (mol:mol)

Size ± sd. (d. nm)

PDI (± sd.)

Zeta Potential (mV)

2:1

3574 ± 493.1

0.264 ± 0.133

-23.0 ± 4.42

4:1

69.62 ± 0.419

0.211 ± 0.014

-16.8 ± 1.36

8:1

-

-

-

Table 2 Effects of EDC to gemcitabine ratio to nanoparticle size most effective at pH 4
PAA:GEM:EDC
(mol:mol:mol)
4:1:2

Size ± sd. (d. nm)

PDI (± sd.)

Zeta Potential (mV)

69.62 ± 0.419

0.211 ± 0.014

-16.8 ± 1.36

4:1:4

2781 ± 0.986

0.986 ± 0.024

-17 ± 1.52

4:1:8

4347± 809.7

1.000 ± 0

-30.8 ± 5.77

8:1:4

43.38 ± 7.635

0.401 ± 0.125

-16.5 ± 0.529

8:1:8

28.74 ± 0.127

0.229 ± 0.006

-15.8 ± 0.802

24

Table 3 Change in size of PAA:GEM nanoparticles with PAA:GEM-RG6 in PBS
Size ± sd. (d. nm)

PDI (± sd.)

Zeta Potential (mV)

PAA:GEM

63.99 ±

0.114 ±

-23.3 ±

PAA:GEM:RG6

59.96 ± 0.926

0.258 ± 0.029

-23.022 ± 1.23

Table 4 Effects of pH for PAA:GEM nanoparticles
pH

Size ± sd. (d. nm)

PDI (± sd.)

Zeta Potential (mV)

4

37.59 ± 0.416

0.142 ± 0.008

-17.4 ± 0.874

5

52.73 ± 0.971

0.242 ± 0.024

-22.7 ± 2.01

6

59.99 ± 1.960

0.169 ± 0.009

-26.2 ±2.2

7.4

57.84 ± 1.909

0.169 ± 0.015

-19.7 ± 1.46
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CHAPTER FOUR: DISCUSSION
The fabrication of the nanoparticles was achieved by carbodiimide chemistry between the
carboxylic acids of PAA and the amine groups of gemcitabine. Several studies have shown the
formation of an amide bond from the amine group of gemcitabine using EDC for the use in
nanoparticles. 49 46 However, no reported study has shown the formation of nanoparticles with the
introduction of EDC to GEM and its conjugated polymer. Here, the formation of the nanoparticles
is driven by the hydrophobic region of GEM collecting in the core of the nanoparticle. Figure 1b,
illustrates the difluoro group within GEM, that results in the hydrophobicity of gemcitabine from
the C-F bond.50 51 The polyelectrolyte PAA then forms an external shell.
Different PAA:GEM ratios were investigated for the fabrication of nanoparticles. For all
ratios, the pH of the solutions was adjusted to 4 with 1M NaOH, as the pKa of gemcitabine and
PAA are 3.6 and 4.2, respectively.11, 52. A pH between the pKa of both materials allows for the
most optimal electrostatic interaction between the positively charged amine of gemcitabine and
the negatively charged carboxylic acid of PAA. The amount of EDC added to each solution was
in excess to GEM for a 2:1 molar ratio of EDC:GEM. The difference in size between the 2:1:2 and
4:1:2 (PAA:GEM:EDC) may have been the result of the amount of GEM collecting in the core of
the nanoparticle that increased the overall size. As the particle is larger and at the same pH there
are more external PAA units in the 2:1:2 ratio compared to the 4:1:2 ratio (PAA:GEM:EDC)
nanoparticles, resulting in a more negatively charged particles.
The effects of EDC to GEM was then investigated with the 4:1 and the 8:1 PAA:GEM ratio
solutions. In the 4:1 PAA:GEM solutions with the increase of EDC the solution became cloudier
and formed micron sized particles, this was the result of a higher collection of GEM in the core
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and higher coupling activity of EDC resulting in loosely formed large particles. The difference in
size between the 8:1 and 4:1 nanoparticles may be a result of higher conjugation of GEM in the
8:1 EDC:GEM samples, resulting in smaller particles as there is a more concentrated hydrophobic
core. As previously seen, the larger particles have a more negative zeta potential as there are more
exterior units of PAA. As a result of the smaller size and low PDI the 8:1:8 PAA:GEM:EDC
nanoparticle was chosen for further studies. A PDI below 0.3 indicates a monodisperse collection
of nanoparticles that may be used for pharmaceutical applications.53
The discrepancy in size between TEM and DLS measurements are a result of the TEM
measurement being investigated in a dried vacuumed state while DLS measurements were taken
while in the hydrodynamic state resulting in sizes of 12.32 ± 1.96 nm and 57.84 ± 1.90 nm in PBS,
respectively.
The attachment of RG6 is coupled through a EDC reaction of the secondary amine of RG6
and the carboxylic acid of PAA. RG6 is slightly hydrophobic due to the aromatic rings, resulting
in the coupling of RG6 to the nanoparticle to occur within the internal pockets of the hydrogel
nanoparticle. The attachment of RG6 demonstrated a slight change in size of the nanoparticles
increasing from 57.84 ± 1.90 nm to 59.96 ± 0.926 nm, when compared to the undecorated PAAGEM nanoparticle. The decrease in surface charge may have been a result of the increase in size
of the nanoparticle as there are more external PAA groups to contribute to the surface charge.
The conjugation between PAA and GEM were confirmed through FT-IR, the formation of
an amide bond is demonstrated in the PAA-GEM samples with the C=O stretching at 1680-1700
cm-1 as the amide I band. The amide II band at 1550-1510 cm-1 is also visible on the PAA-GEM
measurement. The amine stretching from GEM at 3500-3300 cm-1 is not visible in the PAA-GEM
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nanoparticle, due to reaction of the amine. The C-F bond at 1400-1000 cm-1 from GEM is also
shown on the PAA-GEM nanoparticle. As the formation of the amide bond was found within the
PAA-GEM spectrum as well as the C-F band, the conjugation between PAA and gemcitabine was
confirmed.
The encapsulation efficiency of the nanoparticles was demonstrated to be 29 ± 1.66%
compared to other studies where the encapsulation of GEM has been reported in the range 270%.43,

44, 54-56

The loading capacity of GEM recovered was 9.44%, other studies have

demonstrated loading capacities of 0.02-43%.44, 55, 57 The encapsulation efficiency and loading
capacity obtained in this study are within the range of previously reported values.
During the investigation of the stability of the nanoparticles in different pH environments
it was observed that the nanoparticle sizes increased with increasing pH. This is a result of the
nature of a hydrogel nanoparticle; as the pH of the solution increases above the pKa of PAA the
individual carboxylic acid groups begin to deprotonate and ionize. The electrostatic repulsion
between the PAA-GEM nanoparticle results in the swelling of the nanoparticle, which causes the
increase in the size. The increasing ionization also results in more negatively charged surface of
the nanoparticle. Comparing the pH 6 and pH 7.4 solutions, the results do not follow the trend in
increasing size as the pH nanoparticles were resuspended in PBS. The particles may be smaller as
there are more free ions in the PBS solution resulting in a hypertonic solution decreasing the size
of the nanoparticles. Additionally, PBS contains divalent ions such as calcium and magnesium,
bridging of PAA molecules has been demonstrated between divalent ions such as calcium.58 This
bridging effect as well as the hypertonic solution of PBS compared to sodium acetate buffer
resulted in the smaller size and less negative surface of the pH 7.4 resuspended nanoparticles.
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During the in vitro release of PAA-GEM nanoparticles only 6.79% of internalized GEM
was released after 96 hours. Interestingly, the release of GEM may have occurred from unbound
GEM located in the internal pockets of the hydrogel nanoparticle. The remaining GEM is
conjugated via amide bond in the core of the nanoparticle. Other drug delivery studies have shown
an initial burst release from the first few hours where up to 45-70% of the drug can be released.5961

An initial burst release was not demonstrated in the PAA-GEM nanoparticle indicating a slow

and sustained release.
PANC-1 cells, a GEM resistant cell line was used to determine the efficiency of the
nanoparticles.62 Concentrations between the range of 0.01 µM -10 µM were selected to determine
cell toxicity as the IC50 of GEM to various PDAC cell lines fall with this range. The IC50 value for
GEM on PANC-1 cells is 9.5 µM.63 From the cytotoxicity study PAA-GEM nanoparticles did not
show any signs of cell toxicity within the first 48 hours comparted to the free GEM. However, at
96 hours of incubation in the PANC-1 cells the 10 µM PAA-GEM nanoparticles demonstrated
similar cytotoxic efficacy as the free GEM with cell viability at 44.3 ± 3.7% and 42.0 ± 1.6,
respectively. This demonstrated full cytotoxic effects at 96 hour as the IC50 of GEM is 9.5 µM for
PANC-1 cells and ~40% of cells were still viable. In agreement with the in-vitro release study
PAA-GEM nanoparticles reveal a slow release of GEM as shown here. However, the degradation
of PAA-GEM NP needed further investigation.
Cell Uptake studies were preformed to establish if the PAA-GEM nanoparticles were
broken inside the cell or by enzymes in the free growth media. The decorated PAA-GEM-RG6
nanoparticles were incubated in PANC-1 cells. From the results it is seen that the nanoparticles
are internalized as early as 30 minutes and gradually increase until full uptake at 2 hours. The
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uptake of nanoparticles regulates and reaches equilibrium at 2-5 hours. Similar results have been
seen with other polymer nanoparticles where internalization began within 30 minutes and were
fully internalized at 2 hours.40, 64, 65 This data confirms that the degradation of the nanoparticles
occurs after the uptake of the nanoparticles inside the cell.
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CHAPTER FIVE:CONCLUSION
The main objective of this study was to fabricate a nanoparticle with internal gemcitabine
core in order to protect the drug from degradation and protect the subject from cytotoxic effects of
gemcitabine. Here we were able to create a facile fabrication method for nanoparticles using small
hydrophobic molecules and polyelectrolytes. In our study GEM served as our small hydrophobic
molecule and PAA our polyelectrolyte, after conjugation of GEM on to PAA the nanoparticles
formed. The size of the nanoparticles were investigated to be 57.84 ± 1.909 nm in PBS and with a
PDI of 0.169 ± 0.015 in PBS, demonstrating a nanoparticle that can be used for clinical use. The
stability of the nanoparticles were investigated as well, the studies demonstrated that the
nanoparticle had minimal changes in various pH conditions over 7 days. The cytotoxic efficiency
demonstrated a slow release of the drug and overall comparable to free gem after 96 hours. Uptake
study of the nanoparticles into cells was examined as well and full uptake of the nanoparticles
occurred after 2 hours. Overall, we fabricated a nanoparticle that can be used for treatment of
pancreatic cancer.
Future outlooks include the addition of targeting enzymes to the PAA-GEM nanoparticle
to allow for specific cell type targeting. Further modulations can be used to decorate the
nanoparticles including the attachment of other molecules for in vivo bioimaging. The facile
fabrication of the PAA-GEM nanoparticles yielded monodispersed nanoparticles and the methods
can be transferred to create other nanoparticles with hydrophobic molecules and polyelectrolyte.
The method of fabrication demonstrated here is currently under investigation for the fabrication of
PAA-Guanosine-Cerium nanoparticles, for the scavenging of reactive oxygen species. In
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conclusion is that we were able to demonstrate a novel fabrication method of nanoparticles using
only electrolytes and hydrophobic molecules.
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